KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Asset Writedowns and Impairment (2018 - 2024)

Historic Asset Writedowns and Impairment for AbbVie (ABBV) over the last 4 years, with Q4 2024 value amounting to $4.5 billion.

  • AbbVie's Asset Writedowns and Impairment rose 21857.65% to $4.5 billion in Q4 2024 from the same period last year, while for Dec 2024 it was $4.5 billion, marking a year-over-year increase of 584.06%. This contributed to the annual value of $4.5 billion for FY2024, which is 584.06% up from last year.
  • As of Q4 2024, AbbVie's Asset Writedowns and Impairment stood at $4.5 billion, which was up 21857.65% from $1.4 billion recorded in Q4 2023.
  • AbbVie's Asset Writedowns and Impairment's 5-year high stood at $4.5 billion during Q4 2024, with a 5-year trough of $710.0 million in Q1 2023.
  • Moreover, its 3-year median value for Asset Writedowns and Impairment was $1.4 billion (2023), whereas its average is $1.9 billion.
  • In the last 5 years, AbbVie's Asset Writedowns and Impairment soared by 17454.55% in 2023 and then surged by 21857.65% in 2024.
  • AbbVie's Asset Writedowns and Impairment (Quarter) stood at $770.0 million in 2022, then skyrocketed by 82.47% to $1.4 billion in 2023, then soared by 218.58% to $4.5 billion in 2024.
  • Its last three reported values are $4.5 billion in Q4 2024, $1.4 billion for Q4 2023, and $2.1 billion during Q3 2023.